Table 1.
Centers | N | Kogenate | Advate | Kogenate – Advate | ||||||
---|---|---|---|---|---|---|---|---|---|---|
PUPs (n) | Inhibitors (n) | % | PUPs (n) | Inhibitors (n) | % | Absolute difference (%) | 95% CI (%) | |||
All centers | 234 | 124 | 56 | 45 | 110 | 33 | 30 | 15 | 3 | 27 |
Centers 1, 3, and 13* | 73 | 50 | 29 | 58 | 23 | 4 | 17 | 41 | 17 | 47 |
All centers except 1, 3, and 13 | 161 | 74 | 27 | 36 | 87 | 29 | 33 | 3 | −11 | 18 |
Absolute difference was calculated as percentage for Kogenate minus percentage for Advate. A positive value indicates a higher rate with Kogenate. 95% CI was calculated as suggested by Newcombe.2 When the interval does not cross 0, the difference is significant.
Centers with >10 patients on Kogenate (product D) or Advate (product E) and inhibitor rate for Kogenate >50%.